The global dental market is expected roughly to double in size over the next decade. Rising demand for aesthetic treatments, such as implants, veneers and braces, is set to drive the bulk of the growth, particularly in major developed markets such as the US and across Europe. Demand for aesthetic treatments surged immediately after the pandemic as consumers, flush with cash, splashed out on improving their appearance. After several years of growth, demand flattened last year. But according to proprietary analysis by the team at investment bank Berenberg, that’s about to change, particularly in the largest market, the US.
Berenberg’s analysis found that 60% of dentists in the US expect spending on procedures to recover in 2025, driven by enhanced consumer sentiment following Donald Trump’s election. Tax cuts and lower interest rates could also help fuel demand, all of which could be good news for Straumann Holding (Zurich: STMN).
Straumann is a global leader in the tooth replacement and orthodontic procedures market. It develops, produces, and markets dental implants, dental prosthetics, oral orthodontics, and equipment and biomaterials for the dental industry worldwide. Over the past two decades, this market has grown rapidly thanks to the increasing wealth of the middle class and the prevalence of social media – a strong link has been identified between the time spent on social media and the desire for cosmetic procedures. These trends have been substantial tailwinds for the company. Over the past decade, the stock has produced a total return of around 17% per annum.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Straumann's results boosted by a pandemic recovery
When the global economy reopened after the pandemic, Straumann became one of the key beneficiaries as consumers rushed to spend their lockdown savings. Sales surged into 2021, and so did the company’s stock, rising around 100% that year. However, demand slowed after the initial bounce, and revenue followed suit. Investors responded by dumping the stock. The shares lost around half of their value in the following year. And since the end of 2022, the stock has trended sideways as growth has remained elusive.
Berenberg’s analysis suggests that could change in 2025. It pencils in revenue growth of 10% in 2025, followed by about 11% in 2026. Combined with margin expansion, analysts believe this could lead to a 67% increase in earnings before interest and tax (Ebit). The company itself has laid out a target of CHF5 billion in revenue by 2030, up from around CHF2.5 billion estimated for 2024.
Straumann has multiple levers to pull to hit this target. Its analysis suggests the total addressable market (TAM) for key products could be in the region of CHF19 billion, with the most opportunity for growth in the market for clear aligners, the go-to product for teeth straightening. In a market that used to be dominated by old-fashioned braces, clear aligners look better and are more effective. Straumann estimates the TAM here could be worth as much as CHF6 billion per annum – growing at 15%-20% per annum – but its share of the market today is just 3%. In comparison, the company has a 32% share of the global market for dental implants, the fixtures used to support prosthetics.
The other key area of growth, which is a bit more of a wild card due to the level of competition, is in digital products. Products such as imaging and 3D printing have the potential to become a multi-billion market (compared with a few hundred million CHF at present), with a TAM of CHF24 billion, but scale, regulatory, and research and development costs are proving to be major headwinds.
Should you consider buying Straumann Holding?
Straumann’s growth over the next five years is expected to come from premium markets. It is focusing on expanding its presence in high-end orthodontics in key markets, primarily the US. Around 50% of the company’s implants are sold as premium products (and 60% of products across the group), so it already has an established foothold and reputation. Its good reputation allows the company to target premium margins. Its Ebit margin has averaged 26% over the past five years, and management has a margin target range of 25%-30%. New premium products are planned every two to three years and Straumann has historically introduced each new product at a 10%- 15% premium, according to Berenberg’s analysis.
The company has plenty of firepower to maintain its research edge and invest in growth. There’s net cash on the balance sheet and headroom for CHF1 billion-2 billion in leverage for deals, although management has signalled it won’t rush into deals just for the sake of growth. Research and development (benchmarked at around 5% of sales) and the expansion of manufacturing capacity (into the growing Brazilian and Chinese markets) are set to take precedence. Thomas Straumann, the grandson of the company’s founder, is the largest shareholder with a 15.7% stake. He has been a board member since 1990 and is watching over the company’s progress and operational decisions.
Concerns about the company’s growth have weighed on Straumann’s shares over the past six months, and this could present a good opportunity to buy. The stock is trading at an enterprise value to earnings before interest, tax, depreciation, and amortisation (EV/Ebitda) ratio of 22.7, based on Berenberg’s forward projections for 2024, falling to 17.5 on 2026 numbers, both substantially below the ten-year average of 28. Stripping out net cash, expected to hit around CHF500 million by 2026, and the multiple appears even more attractive.
This article was first published in MoneyWeek's magazine. Enjoy exclusive early access to news, opinion and analysis from our team of financial experts with a MoneyWeek subscription.
-
Review: Shangri-La Paris – an ode to the world’s best foodNatasha Langan enjoys fine French and Chinese cuisine at the Shangri-La Paris
-
Two top Asia-focused investment trustsPacific Assets and Scottish Oriental are both trusts that focus on high-quality companies controlled by trustworthy families or founders
-
The star small and mid-cap stocks income investors have overlookedOpinion Thomas Moore, senior investment director, Aberdeen, highlights three company stocks as he shares where he would put his money
-
Falling revenues and mounting debt spell trouble for Jumia TechnologiesStruggling African e-commerce platform Jumia Technologies looks headed for the exit, says Dr Matthew Partridge.
-
Chemring Group: an explosive investment opportunity in defenceEuropean states are raising their military spending, and Chemring Group looks well placed to profit
-
Best of British bargains: cash in on undervalued companies in the UK stock marketOpinion Michael Field, Chief Equity Market Strategist, EMEA, Morningstar, selects three attractive UK stocks where he'd put his money
-
PZ Cussons share price down 75% in last decade – why it's one to watchOpinion Once-strong consumer-goods business PZ Cussons is out of favour with the market. That spells opportunity for investors, says Jamie Ward
-
Cash in on the biotech sector with specialist trust BioPharmaOpinion BioPharma has an attractive niche in lending to asset-rich biotechnology companies
-
Three top-notch Taiwanese companies cashing in on the advent of AIOpinion Eric Chan, investment director and co-manager of the Aberdeen Asian Income Fund, highlights three potential Taiwanese winners in the technology industry
-
Find tomorrow’s Asian giants while they are still smaller companiesOpinion Nitin Bajaj, portfolio manager of the Fidelity Asian Values trust, picks three Asian companies to invest in.
